[
    [
        {
            "time": "2018-09-15",
            "original_text": "Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range",
            "features": {
                "keywords": [
                    "Novartis",
                    "CEO",
                    "gene therapy",
                    "price",
                    "lower",
                    "million"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-09-15",
            "original_text": "Novartis Is a Difficult Stock to Trade or Own - Suggested Risk Point",
            "features": {
                "keywords": [
                    "Novartis",
                    "Difficult",
                    "Stock",
                    "Trade",
                    "Own",
                    "Risk"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 5,
                "Impact": 4,
                "Duration": 2,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-09-15",
            "original_text": "The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study",
            "features": {
                "keywords": [
                    "Biotech",
                    "Tocagen",
                    "OncoSec",
                    "Offering",
                    "Novartis",
                    "Asthma",
                    "Combo",
                    "Drug",
                    "Study"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-09-15",
            "original_text": "3 Bearish Takeaways From the Tilray Earnings Report",
            "features": {
                "keywords": [
                    "Bearish",
                    "Takeaways",
                    "Tilray",
                    "Earnings",
                    "Report"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "cannabis",
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 6,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        }
    ]
]